Sign In
Buy MDGL
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
12:00pm, Wednesday, 07'th Sep 2022 GlobeNewswire Inc.
CONSHOHOCKEN, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohep
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results
12:00pm, Thursday, 04'th Aug 2022 GlobeNewswire Inc.
CONSHOHOCKEN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepat
Madrigal: Buy And Hoard Before Q4 Data Readout
08:34am, Thursday, 04'th Aug 2022
Madrigal will have a key catalytic event in Q4. This is the data from the ~900 patient subpart H population of biopsy-proven NASH patients.
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022
02:02pm, Friday, 08'th Jul 2022 Benzinga
Upgrades
According to Wedbush, the prior rating for Diebold Nixdorf Inc (NYSE:DBD) was changed from Neutral to Outperform. Diebold Nixdorf earned $1.61 in the first quarter, compared to $0.29 in the
Trial Results Set to Make or Break Small-Cap Pharma Stocks
04:15pm, Wednesday, 06'th Jul 2022
One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administrati
Analysts Believe Madrigal's Resmetirom Shows Impressive Overall Profile In Liver Fibrosis
12:50pm, Monday, 27'th Jun 2022
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) presented multiple resmetirom abstracts at the European Association for the Study of the Liver's International Liver Congress. The data included new deta
Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™
01:00pm, Saturday, 25'th Jun 2022 GlobeNewswire Inc.
CONSHOHOCKEN, Pa., June 25, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepat
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
12:00pm, Thursday, 02'nd Jun 2022 GlobeNewswire Inc.
CONSHOHOCKEN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohep
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
08:00am, Thursday, 02'nd Jun 2022
CONSHOHOCKEN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepat
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
12:00pm, Tuesday, 17'th May 2022 GlobeNewswire Inc.
CONSHOHOCKEN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepa
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
08:00am, Tuesday, 17'th May 2022
CONSHOHOCKEN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepati
Madrigal Pharmaceuticals, Inc. (MDGL) CEO Paul Friedman on Q1 2022 Results - Earnings Call Transcript
12:56pm, Monday, 09'th May 2022
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Q1 2022 Results Earnings Conference Call May 9, 2022 8:00 AM ET Company Participants Paul Friedman - Chairman and Chief Executive Officer Rebecca Taub - F
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results
10:30am, Monday, 09'th May 2022 GlobeNewswire Inc.
Company to host conference call at 8:00 AM ET, May 9th, 2022
Madrigal: Clear Path Ahead
02:09pm, Friday, 22'nd Apr 2022
Among many non-alcoholic steatohepatitis (NASH) drug innovators, Madrigal Pharmaceuticals is poised to deliver the first medicine to the market sometime next year. By Q4 this year, the company is anti
Madrigal: NASH Data In Q4 Is The Key
12:35pm, Tuesday, 19'th Apr 2022
MDGL announced NAFLD data in January. The 2018 NASH data has some predictive value for the phase 3 NASH trial.
